Janssen Vaccines
52°09′56″N 4°28′02″E / 52.1655°N 4.4673°E
Parent Johnson & Johnson | | |
Website | www |
---|
Janssen Vaccines, formerly Crucell, is a
History
In 1993
In 2006, Crucell and Swiss Berna Biotech; Swedish SBL Vaccines and US-based Berna Products joined forces to become the sixth largest vaccine company worldwide, with their own clinical programs.[citation needed]
On 7 January 2009 Crucell released a press release saying Crucell and Wyeth were in discussion on a merger of the two companies. On 26 January 2009 Crucell released another press release saying the discussions on a combination of Crucell and Wyeth was discontinued due to Pfizer's acquisition of Wyeth.[citation needed]
In September 2009 Johnson & Johnson bought 18% stake in Crucell for €302 million in order to collaborate on the development of a flu vaccine.[1] This followed Crucell's discovery of CR6261, a potent human antibody that neutralizes a broad range of influenza A viruses. J&J acquired the rest of the company in October 2010, taking its stake to over 95% by February 2011[2][3] and delisting the company from stock exchanges two months later.[4]
After the takeover by Johnson & Johnson in 2011, Crucell was assigned to Janssen Pharmaceuticals division. In 2014, the subsidiary was renamed from Crucell to Janssen Vaccines.[5][6]
COVID-19 vaccine development
Janssen Vaccines in Leiden developed the
References
- ^ Gray-Block, Aaron (28 September 2009). "Johnson & Johnson buys 18 pct stake in Crucell". Reuters. Retrieved 28 September 2009.
- Dow Jones Newswires. Retrieved 27 February 2011.
- ^ "J&J aiming to buy vaccine maker Crucell for $2.3 billion". Reuters. 17 September 2010.
- ^ Gray-Block, Aaron (11 April 2011). "Crucell to be delisted after J&J buyout". Reuters. Retrieved 16 April 2011.
- ^ "Crucell". DevEx. 2015.
- ^ "Janssen Vaccines AG". Company Profiles. Bloomberg. 2020.